Capital spending by Nigeria’s five listed pharmaceutical manufacturers rose 81% to N29.26 billion during 2026's first three quarters, BusinessDay reported, as companies sought to expand production.
BusinessDay said the investment was intended to expand manufacturing capacity. Earlier EconoTimes coverage has examined imported active-ingredient risks facing Nigerian drugmakers.



